These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 15703360

  • 1. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis.
    Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, Lee H.
    J Clin Pharmacol; 2005 Mar; 45(3):246-56. PubMed ID: 15703360
    [Abstract] [Full Text] [Related]

  • 2. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H, Mayer PR, Wajdula J, Fatenejad S.
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [Abstract] [Full Text] [Related]

  • 3. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ.
    Arthritis Rheum; 2004 Feb; 50(2):353-63. PubMed ID: 14872476
    [Abstract] [Full Text] [Related]

  • 4. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
    Elewski B, Leonardi C, Gottlieb AB, Strober BE, Simiens MA, Dunn M, Jahreis A.
    Br J Dermatol; 2007 Jan; 156(1):138-42. PubMed ID: 17199580
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.
    Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO, Li J, Louie J, Furst DE.
    Arthritis Rheum; 2008 Jul; 58(7):1921-30. PubMed ID: 18576334
    [Abstract] [Full Text] [Related]

  • 6. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.
    Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Lange M, Finck BK, Burge DJ, Pediatric Rheumatology Collaborative Study Group.
    Arthritis Rheum; 2003 Jan; 48(1):218-26. PubMed ID: 12528122
    [Abstract] [Full Text] [Related]

  • 7. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein.
    Zhou H.
    J Clin Pharmacol; 2005 May; 45(5):490-7. PubMed ID: 15831771
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis.
    Horneff G, Ebert A, Fitter S, Minden K, Foeldvari I, Kümmerle-Deschner J, Thon A, Girschick HJ, Weller F, Huppertz HI.
    Rheumatology (Oxford); 2009 Aug; 48(8):916-9. PubMed ID: 19483091
    [Abstract] [Full Text] [Related]

  • 9. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.
    Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, Robinson M, Kim J, Barron KS.
    Arthritis Rheum; 2005 Feb 15; 53(1):18-23. PubMed ID: 15696578
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis.
    Takei S, Groh D, Bernstein B, Shaham B, Gallagher K, Reiff A.
    J Rheumatol; 2001 Jul 15; 28(7):1677-80. PubMed ID: 11469478
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis.
    Nestorov I, Zitnik R, DeVries T, Nakanishi AM, Wang A, Banfield C.
    Br J Clin Pharmacol; 2006 Oct 15; 62(4):435-45. PubMed ID: 16995864
    [Abstract] [Full Text] [Related]

  • 12. Etanercept therapy in children with juvenile rheumatoid arthritis.
    Hung JJ, Huang JL.
    J Microbiol Immunol Infect; 2005 Dec 15; 38(6):444-6. PubMed ID: 16341346
    [Abstract] [Full Text] [Related]

  • 13. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
    Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore JB, White B, Giannini EH, Pediatric Rheumatology Collaborative Study Group.
    Arthritis Rheum; 2006 Jun 15; 54(6):1987-94. PubMed ID: 16732547
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of etanercept dose reduction in patients with rheumatoid arthritis using pharmacokinetic/pharmacodynamic modeling and simulation.
    Hsu LF, Huang JD.
    Int J Clin Pharmacol Ther; 2014 Sep 15; 52(9):776-86. PubMed ID: 24887337
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.
    Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, Baumgartner SW, Giannini EH, Pediatric Rheumatology Collaborative Study Group.
    Arthritis Rheum; 2008 May 15; 58(5):1496-504. PubMed ID: 18438876
    [Abstract] [Full Text] [Related]

  • 16. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.
    van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, Olivieri I, Raeman F, Settas L, Sieper J, Szechinski J, Walker D, Boussuge MP, Wajdula JS, Paolozzi L, Fatenejad S, Etanercept Study 314 Investigators.
    Ann Rheum Dis; 2006 Dec 15; 65(12):1572-7. PubMed ID: 16968715
    [Abstract] [Full Text] [Related]

  • 17. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
    Braun J, McHugh N, Singh A, Wajdula JS, Sato R.
    Rheumatology (Oxford); 2007 Jun 15; 46(6):999-1004. PubMed ID: 17389658
    [Abstract] [Full Text] [Related]

  • 18. Treatment with etanercept for patients with juvenile rheumatoid arthritis in Taiwan--a preliminary report.
    Liang TC, Yang YH, Lin YT, Chiang BL.
    J Microbiol Immunol Infect; 2005 Dec 15; 38(6):447-50. PubMed ID: 16341347
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
    Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T.
    J Am Acad Dermatol; 2006 Mar 15; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
    [Abstract] [Full Text] [Related]

  • 20. Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis.
    Kietz DA, Pepmueller PH, Moore TL.
    J Rheumatol; 2001 Feb 15; 28(2):360-2. PubMed ID: 11246677
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.